Mesenchymal stem cells (MSC) prevented the progression of renovascular hypertension, improved renal function and architecture
- PMID: 24223811
- PMCID: PMC3817204
- DOI: 10.1371/journal.pone.0078464
Mesenchymal stem cells (MSC) prevented the progression of renovascular hypertension, improved renal function and architecture
Abstract
Renovascular hypertension induced by 2 Kidney-1 Clip (2K-1C) is a renin-angiotensin-system (RAS)-dependent model, leading to renal vascular rarefaction and renal failure. RAS inhibitors are not able to reduce arterial pressure (AP) and/or preserve the renal function, and thus, alternative therapies are needed. Three weeks after left renal artery occlusion, fluorescently tagged mesenchymal stem cells (MSC) (2×10(5) cells/animal) were injected weekly into the tail vein in 2K-1C hypertensive rats. Flow cytometry showed labeled MSC in the cortex and medulla of the clipped kidney. MSC prevented a further increase in the AP, significantly reduced proteinuria and decreased sympathetic hyperactivity in 2K-1C rats. Renal function parameters were unchanged, except for an increase in urinary volume observed in 2K-1C rats, which was not corrected by MSC. The treatment improved the morphology and decreased the fibrotic areas in the clipped kidney and also significantly reduced renal vascular rarefaction typical of 2K-1C model. Expression levels of IL-1β, TNF-α angiotensinogen, ACE, and Ang II receptor AT1 were elevated, whereas AT2 levels were decreased in the medulla of the clipped kidney. MSC normalized these expression levels. In conclusion, MSC therapy in the 2K-1C model (i) prevented the progressive increase of AP, (ii) improved renal morphology and microvascular rarefaction, (iii) reduced fibrosis, proteinuria and inflammatory cytokines, (iv) suppressed the intrarenal RAS, iv) decreased sympathetic hyperactivity in anesthetized animals and v) MSC were detected at the CNS suggesting that the cells crossed the blood-brain barrier. This therapy may be a promising strategy to treat renovascular hypertension and its renal consequences in the near future.
Conflict of interest statement
Figures






Similar articles
-
Renovascular hypertension: Effects of mesenchymal stem cells in the contralateral hypertensive kidney in rats.Clin Exp Hypertens. 2016;38(7):586-593. doi: 10.3109/10641963.2016.1174253. Epub 2016 Sep 20. Clin Exp Hypertens. 2016. PMID: 27649588
-
Transplantation of bone marrow-derived MSCs improves renal function and Na++K+-ATPase activity in rats with renovascular hypertension.Cell Tissue Res. 2017 Aug;369(2):287-301. doi: 10.1007/s00441-017-2602-3. Epub 2017 Apr 3. Cell Tissue Res. 2017. PMID: 28374150
-
Treatment with Mesenchymal Stem Cells Improves Renovascular Hypertension and Preserves the Ability of the Contralateral Kidney to Excrete Sodium.Kidney Blood Press Res. 2019;44(6):1404-1415. doi: 10.1159/000503346. Epub 2019 Oct 31. Kidney Blood Press Res. 2019. PMID: 31671420
-
Effects of mesenchymal stem cells in renovascular hypertension.Exp Physiol. 2015 Apr 20;100(5):491-5. doi: 10.1113/expphysiol.2014.080531. Epub 2015 Feb 25. Exp Physiol. 2015. PMID: 25605443 Review.
-
Mesenchymal stem cells and chronic renal artery stenosis.Am J Physiol Renal Physiol. 2016 Jan 1;310(1):F6-9. doi: 10.1152/ajprenal.00341.2015. Epub 2015 Nov 4. Am J Physiol Renal Physiol. 2016. PMID: 26538439 Review.
Cited by
-
Stem cells prevent long-term deterioration of renal function after renal artery revascularization in a renovascular hypertension model in rats.Sci Rep. 2025 Jan 27;15(1):3397. doi: 10.1038/s41598-025-87451-4. Sci Rep. 2025. PMID: 39870783 Free PMC article.
-
State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.Am J Physiol Heart Circ Physiol. 2022 Apr 1;322(4):H647-H680. doi: 10.1152/ajpheart.00674.2021. Epub 2022 Feb 18. Am J Physiol Heart Circ Physiol. 2022. PMID: 35179976 Free PMC article. Review.
-
Cardiovascular Effects of Autologous Bone Marrow-Derived Mesenchymal Stromal Cell Therapy With Early Tacrolimus Withdrawal in Renal Transplant Recipients: An Analysis of the Randomized TRITON Study.J Am Heart Assoc. 2021 Dec 21;10(24):e023300. doi: 10.1161/JAHA.121.023300. Epub 2021 Dec 16. J Am Heart Assoc. 2021. PMID: 34913362 Free PMC article. Clinical Trial.
-
Increased cellular senescence in the murine and human stenotic kidney: Effect of mesenchymal stem cells.J Cell Physiol. 2021 Feb;236(2):1332-1344. doi: 10.1002/jcp.29940. Epub 2020 Jul 13. J Cell Physiol. 2021. PMID: 32657444 Free PMC article.
-
Mesenchymal Stem Cells and Their Exocytotic Vesicles.Int J Mol Sci. 2023 Jan 20;24(3):2085. doi: 10.3390/ijms24032085. Int J Mol Sci. 2023. PMID: 36768406 Free PMC article. Review.
References
-
- Chade AR, Rodriguez-Porcel M, Grande JP, Krier JD, Lerman A, et al. (2002) Distinct renal injury in early atherosclerosis and renovascular disease. Circulation 106: 1165–1171. - PubMed
-
- Chade AR, Rodriguez-Porcel M, Grande JP, Zhu X, Sica V, et al. (2003) Mechanisms of renal structural alterations in combined hypercholesterolemia and renal artery stenosis. Arterioscler Thromb Vasc Biol 23: 1295–1301. - PubMed
-
- Chade AR, Zhu X, Mushin OP, Napoli C, Lerman A, et al.. (2006) Simvastatin promotes angiogenesis and prevents microvascular remodeling in chronic renal ischemia. Faseb J 20: 1706 –1708. - PubMed
-
- Ploth DW (1983) Angiotensin-dependent renal mechanisms in two-kidney one-clip renal vascular hypertension. Am J Physiol 245: 131–141. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous